Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharma acquires AB Sanitas
Previously, Valeant signed a deal to take over Lithuania-based specialty pharmaceuticals company AB Sanitas for around EUR314m. Sanitas has a range of branded generics product portfolio consisting of
Previously, Valeant signed a deal to take over Lithuania-based specialty pharmaceuticals company AB Sanitas for around EUR314m. Sanitas has a range of branded generics product portfolio consisting of
The drug has been approved for the patients with Hodgkin lymphoma and for the patients suffering from systemic anaplastic large cell lymphoma (ALCL). The approvals were given on
With this acquisition, Atrium will take over a manufacturing plant and process that is approved by different regulatory bodies in countries where Wobenzym products are sold. Atrium distributes
The projects – aimed at treating conditions such as vision loss, neurodegenerative disease and depression – are funded through the NIH Blueprint for Neuroscience Research. The NIH Blueprint
Furiex will use the loan to support research and development for clinical stage compounds JNJ-Q2, MuDelta and PPD10558. Furiex Pharmaceuticals chief financial officer, treasurer and assistant secretary Marshall
The company informed that at a median of 17 months follow-up, the relapse rate in patients with low levels of HER2 expression treated with AE37 is half that
Focalin is used in the treatment of attention deficit hyperactivity disorder (ADHD). Intellipharmaceutics will receive a cash amount from Par and will continue to obtain a share of
Vecuronium bromide for injection is indicated for the patients with myasthenia gravis or the myasthenic (Eaton-Lambert) syndrome (muscle weakness/fatigue). The injection features Sagent’s PreventIV Measures packaging and labeling
The results from Phase 2b study suggested that lasmiditan achieved its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours
The company has previously released positive results from a Phase II (DTCL100) trial evaluating KRN5500, which demonstrated reduction of pain and safety and was superior to placebo. Based